Higher Scientific Officer, Cancer Biomarkers Team
Posted 11 days 13 hours ago by THE INSTITUTE OF CANCER RESEARCH
Salary: Commencement on the salary range is subject to comparable skills and experience. Future progression is based on annual performance review.
This role is eligible for ICR Sponsorship. Support will be provided for costs associated with Visa application. If you are considering relocating to the UK, further information can be found here .
Duration of Contract: Fixed Term for 12 months
Hours per week: 35 hours per week (Full Time)
Closing Date: 5th January 2025
There is an urgent need to expand the use of histopathology-based techniques to support our drug discovery/development activities. A Higher Scientific Officer is required to join a team involved in the expansion of the facilities for histopathology, immunohistochemistry, and multiplex immunofluorescence to support studies on prognostic, diagnostic and pharmacodynamic markers of response. The post holder will support the day-to-day operations, offer histological expertise, accurately record and communicate lab results and train team members to enhance their skills and ensure successful project outcomes. They will also ensure scientific work is accurate and efficient, comply with health and safety regulations, and write risk assessments and standard operating procedures.
Key Requirements
Candidates must have significant expertise in a range of histopathology techniques including tissue processing, embedding, sectioning of both paraffin embedded and frozen samples, automated immunohistochemistry and immunofluorescence, and antibody optimisation.
They should possess a first degree (or equivalent) in biomedical science, molecular biology/pharmacology or related subject. An understanding of GCP would be an advantage.
Department/Directorate Information
Professor Johann de Bono's team conducts biomarker-driven clinical and translational research to accelerate the development of novel cancer therapies and improve understanding of cancer biology, drug sensitivity and resistance. His team focuses on improving prostate cancer care that have led pivotal phase III trials of several prostate cancer drugs including abiraterone, cabazitaxel, enzalutamide and olaparib as well as more recently ipatasertib and lutetium-PSMA. His team consists of basic and clinical scientists, which is embedded in a vibrant world-class research environment.
We encourage all applicants to access the job pack attached for more detailed information regarding this role. For an informal discussion regarding the role, please contact Mateus Crespo via email on .
Due to the high volumes of applications that we receive, we reserve the right to close the advert before the published closing date, once we have received a sufficient number of applications. Therefore, we advise that you submit your application as early as possible to avoid disappointment.
About The Institute of Cancer ResearchWhy work for us?
As a member of staff, you'll have exclusive access to a range of staff benefits.
The ICR is committed to supporting overseas applicants applying for roles; please click here to find out further information.
The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. Further information about working at the ICR can be found here .
We look forward to receiving applications from all candidates, wherever in the world they are currently based. We will select those who display the potential to become, or to support, the world leading cancer researchers of the future based on their application and performance at interview. However, we particularly welcome British applicants from black and ethnic minority backgrounds, as they are under-represented within the ICR and nationwide in STEM roles.